Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

IL-33 anticorps

IL33 Reactivité: Humain WB, ELISA, IHC, IP, Func Hôte: Souris Monoclonal IL33305B unconjugated
N° du produit ABIN1169172
  • Antigène Voir toutes IL-33 (IL33) Anticorps
    IL-33 (IL33) (Interleukin 33 (IL33))
    Reactivité
    • 85
    • 48
    • 38
    • 9
    • 1
    Humain
    Hôte
    • 105
    • 27
    • 8
    • 2
    • 2
    • 1
    • 1
    Souris
    Clonalité
    • 116
    • 30
    Monoclonal
    Conjugué
    • 74
    • 23
    • 13
    • 7
    • 5
    • 5
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp IL-33 est non-conjugé
    Application
    • 88
    • 70
    • 36
    • 28
    • 18
    • 15
    • 14
    • 14
    • 12
    • 11
    • 9
    • 5
    • 5
    • 5
    • 4
    • 4
    • 4
    • 3
    • 2
    Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), Functional Studies (Func)
    Specificité
    Recognizes human IL-33.
     Réactivité croisée
    Humain
    Aucune reactivité croisée
    Souris
    Réactivité croisée (Details)
    Does not cross-react with mouse IL-33.
    Stérilité
    0.2 μm filtered
    Immunogène
    Recombinant human IL-33.
    Clone
    IL33305B
    Isotype
    IgG2a
    Top Product
    Discover our top product IL33 Anticorps primaire
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    Lot specific
    Buffer
    0.2μm-filtered solution in PBS, pH 7.4. Contains no preservatives.
    Agent conservateur
    Without preservative
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Short Term Storage: +4°C
    Long Term Storage: -20°C
    Stable for at least 1 year after receipt when stored at -20°C.
    Date de péremption
    12 months
  • Pace, Di Sano, Sciarrino, Scafidi, Ferraro, Chiappara, Siena, Gangemi, Vitulo, Giarratano, Gjomarkaj: "Cigarette smoke alters IL-33 expression and release in airway epithelial cells." dans: Biochimica et biophysica acta, Vol. 1842, Issue 9, pp. 1630-7, (2014) (PubMed).

    Palmer, Talabot-Ayer, Lamacchia, Toy, Seemayer, Viatte, Finckh, Smith, Gabay: "Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis." dans: Arthritis and rheumatism, Vol. 60, Issue 3, pp. 738-49, (2009) (PubMed).

    Chapuis, Hot, Hansmannel, Kerdraon, Ferreira, Hubans, Maurage, Huot, Bensemain, Laumet, Ayral, Fievet, Hauw, DeKosky, Lemoine, Iwatsubo, Wavrant-Devrièze, Dartigues, Tzourio, Buée, Pasquier, Berr et al.: "Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. ..." dans: Molecular psychiatry, Vol. 14, Issue 11, pp. 1004-16, (2009) (PubMed).

    Talabot-Ayer, Lamacchia, Gabay, Palmer: "Interleukin-33 is biologically active independently of caspase-1 cleavage." dans: The Journal of biological chemistry, Vol. 284, Issue 29, pp. 19420-6, (2009) (PubMed).

  • Antigène
    IL-33 (IL33) (Interleukin 33 (IL33))
    Autre désignation
    IL-33 (IL33 Produits)
    Synonymes
    anticorps IL33, anticorps C9orf26, anticorps DVS27, anticorps IL1F11, anticorps NF-HEV, anticorps NFEHEV, anticorps RP11-575C20.2, anticorps 9230117N10Rik, anticorps Il-33, anticorps Il1f11, anticorps RGD1311155, anticorps interleukin 33, anticorps IL33, anticorps Il33
    Sujet
    Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The 30 kDa human IL33 is converted by CASP1 to a 18 kDa protein. IL33 binds to and signals through ST2 (IL1R1) and its stimulation recruits MYD88, IRAK, IRAK4, and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38(MAPK14), and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells, and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases, and sepsis.
    UniProt
    O95760
    Pathways
    Production of Molecular Mediator of Immune Response
Vous êtes ici:
Support technique